CLAIMS

1. Use of chymotrypsinogen and trypsinogen in the manufacture of a medicament for minimising the progression of cancer in a subject, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1, wherein the subject has previously received a treatment for cancer.

2. Use of chymotrypsinogen and trypsinogen in the manufacture of a medicament for treating minimal residual disease in a subject who has received a treatment for cancer, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.

3. Use of a therapeutically effective amount of chymotrypsinogen and trypsinogen in the manufacture of a medicament for preventing recurrence of cancer in a subject who has received a treatment for cancer, wherein the weight ratio of chymotrypsinogen: trypsinogen is in the range of between 4:1 to 8:1.

4. A use according to any one of claims 1 to 3, wherein the treatment for cancer is selected from the group consisting of surgical excision of the tumour, radiotherapy, chemotherapy, immunotherapy or a combination thereof.

5. Use of a therapeutically effective amount of chymotrypsinogen and trypsinogen in the manufacture of a medicament for preventing cancer in a subject, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.

6. Use of a therapeutically effective amount of chymotrypsinogen and trypsinogen in the manufacture of a medicament for delaying the onset of cancer in a subject, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.

7. A use according to claim 5 or 6, wherein the subject is one who is identified as being at risk of cancer.

8. A use according to claim 7, wherein the risk of cancer is determined on the basis of family medical history, or biomarkers associated with risk of cancer, or a combination thereof.

9. A use according to any one of claims 5 to 8, wherein the subject has not been diagnosed as having cancer.

10. A use according to any one of the preceding claims wherein the individual does not have detectable cancer at the time that the chymotrypsinogen and trypsinogen are administered.

11. A use according to any one of the preceding claims wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 5:1 to 7:1.

12. A use according to claim 11 wherein the weight ratio of chymotrypsinogen: trypsinogen is about 6:1.

13. A use according to any one of the preceding claims wherein the number of cancer stem cells in the subject is reduced or prevented from increasing in number following administration of the medicament.

14. A use according to any one of the preceding claims, wherein the cancer stem cells are differentiated following administration of the medicament.

15. A use according to any one of the preceding claims, wherein the cancer is selected from the group consisting of pancreatic cancer, colon cancer, neuroblastoma, ovarian cancer, non-small cell lung cancer, skin cancer, oesophageal cancer, lung cancer and breast cancer.